Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.71 |
| ▸ | DRD3 | P35462 | 3/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.64 |
| ▸ | HTR3B | O95264 | 1/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | HTR3A | P46098 | 1/20 | 0.64 |
| ▸ | HTR6 | P50406 | 1/20 | 0.64 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.64 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL327835 | 0.83 | DRD2 (1.00) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| SCHEMBL30407688 | 0.82 | DRD2 (0.72) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| SCHEMBL3165674 | 0.82 | DRD2 (0.72) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| SCHEMBL11150752 | 0.81 | DRD2 (0.71) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| SCHEMBL3399759 | 0.81 | DRD2 (0.71) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL8576226 | 0.81 | DRD2 (0.96) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| SCHEMBL2822342 | 0.81 | DRD2 (0.71) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| SCHEMBL1484038 | 0.81 | DRD2 (0.71) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| SCHEMBL3020451 | 0.81 | DRD2 (0.70) | DRD2DRD3CYP2C19HTR3EHTR3B | |
| SCHEMBL3174809 | 0.81 | DRD2 (0.70) | DRD2DRD3CYP2C19HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496084-B1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS INC (US) | 2015-06-10 | — | — | EP | claimed |
| US-8309537-B2 | Compositions and methods for treating colitis | AERPIO THERAPEUTICS INC. (US) | 2012-11-13 | — | — | US | claimed |
| CN-102638983-A | Compositions and methods for treating colitis | AKEBIA THERAPEUTICS INC | 2012-08-15 | — | — | CN | claimed |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | claimed |
| US-5378690-A | Treatment of angiotensin induced hypertension | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | claimed |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| EP-3698794-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | Aerpio Therapeutics, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3603644-A1 | PROLYL HYDROXYLASE INHIBITORS | Aerpio Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-2952192-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20190055198-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2019-02-21 | — | — | US | disclosed |
| US-20170298019-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2017-10-19 | — | — | US | disclosed |
| WO-2010045580-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | EXELIXIS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| US-6342503-B1 | ANTIDEPRESSANTS, EATING DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2002-01-29 | — | — | US | disclosed |
| US-5789409-A | ANTIINFLAMMATORY AGENTS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1998-08-04 | — | — | US | disclosed |
| US-5378690-A | Treatment of angiotensin induced hypertension | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | disclosed |
| US-4918074-A | CALCIUM ANTAGONISTS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1990-04-17 | — | — | US | disclosed |
| US-4775757-A | CARDIOTONIC AND RENAL VASODILATING AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-10-04 | — | — | US | disclosed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | disclosed |
| EP-0217142-A2 | A polyazaheterocyclic compound | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1987-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298019-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | DRD2 4616/4885DRD3 4787/4885CYP2C19 4174/4885 |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | ALPI, SI, SLC10A2 | DRD2 4189/4885DRD3 3680/4885CYP2C19 1222/4885 |
| US-20190055198-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | DRD2 4616/4885DRD3 4787/4885CYP2C19 4174/4885 |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | DRD2 4616/4885DRD3 4787/4885CYP2C19 4174/4885 |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | HIF1AN, HIF1A, EGLN2 | DRD2 4616/4885DRD3 4787/4885CYP2C19 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.